Properties (55)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:Company
|
| gptkbp:availableIn |
generic drug
|
| gptkbp:brand |
Sulfatrim
|
| gptkbp:chemicalFormula |
C12H14N4O3S
|
| gptkbp:clinicalTrials |
Phase IV
Phase II Phase III Phase I WHO guidelines CDC_guidelines IDSA_guidelines |
| gptkbp:composedOf |
chemical synthesis
acylation reaction reduction of sulfanilamide |
| gptkbp:contraindication |
liver toxicity
pregnancy kidney toxicity blood dyscrasias hypersensitivity to sulfonamides |
| gptkbp:developedBy |
pharmaceutical companies
|
| gptkbp:drugInterdiction |
bacteriostatic
crosses blood-brain barrier crosses placenta distributes widely in tissues well absorbed orally |
| gptkbp:endOfLife |
6 to 12 hours
|
| gptkbp:formulation |
suspension
injectable solution |
| https://www.w3.org/2000/01/rdf-schema#label |
Sulfamethazine
|
| gptkbp:interactsWith |
diuretics
warfarin methotrexate |
| gptkbp:isATypeOf |
57-68-1
|
| gptkbp:issuedBy |
oral tablet
|
| gptkbp:lastProduced |
1950s
|
| gptkbp:mandates |
urinary tract infections
gastrointestinal infections respiratory tract infections |
| gptkbp:marketedAs |
gptkb:Australia
gptkb:Canada gptkb:European_Union gptkb:United_States |
| gptkbp:nutritionalValue |
liver
|
| gptkbp:operates_in |
J01EB02
|
| gptkbp:relatedPatent |
sulfadiazine
sulfamethoxazole sulfisoxazole |
| gptkbp:route |
oral
|
| gptkbp:safetyFeatures |
Category C
|
| gptkbp:sideEffect |
nausea
diarrhea skin rash |
| gptkbp:triggerType |
inhibits bacterial folic acid synthesis
|
| gptkbp:usedFor |
bacterial infections
|
| gptkbp:waterManagement |
urine
|